O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

Prelaunch activity of Metformin+Glimepiride combination

2.345 visualizações

Publicada em

Prelaunch activity of Metformin+Glimepiride combination

Publicada em: Saúde e medicina
  • Seja o primeiro a comentar

Prelaunch activity of Metformin+Glimepiride combination

  1. 1. MARKET SURVEY OF DOCTOR PREFERENCE ON GLIMEPIRIDE + METFORMIN AS A PART OF PRELAUNCH ACTIVITY AT MEDPAAR PHARMACEUTICALS A PROJECT REPORT On behalf of MEDPAAR PHARMACEUTICALS Submitted by AMITSINH VIHOL in partial fulfillment for the award of the degree of MASTER OF BUSINESS ADMINISTRATION IN PHARMA MANAGEMENT Under the guidance of GUIDE CO-GUIDE Dr. Shrikalp S. Deshpande Mr. Charming A. Vakil KADI SARVA VISHWA VIDYALAYA. APRIL 2014
  2. 2. MARKET SURVEY OF DOCTOR PREFERENCE ON GLIMEPIRIDE + METFORMIN AS A PART OF PRELAUNCH ACTIVITY AT MEDPAAR PHARMACEUTICALS A PROJECT REPORT On behalf of MEDPAAR PHARMACEUTICALS Submitted by AMITSINH VIHOL in partial fulfillment for the award of the degree of MASTER OF BUSINESS ADMINISTRATION IN PHARMA MANAGEMENT Under the guidance of GUIDE CO-GUIDE Dr. Shrikalp S. Deshpande Mr. Charming A. Vakil KADI SARVA VISHWA VIDYALAYA. APRIL 2014
  3. 3. PFIARMACET]TICALS Reg.&CorporateOffice: TF- 07,3" Floor,Agrawal.Mall,Opp.BhagwatVidhyapith,9c. Highway,Sola,Ahmedabad-38oo60(Gujarat) Ph: 9033649833,9724352581website:wwwmedpiarptrarmi.cbm,Emait:-medfaarpharma@gmail.com Date:l-5'nApril,2OI4 TOWHOMSOEVERITMAYCONCERN Thisisto certifythat Mr. AMITSINHV|HOLfromKADISARVAVISHWAVIDYALAYAMBA PHARMA,GANDHINAGARhas successfullycompletedhis major projectin our companyon ,,MARKET SURVEYOF DOCTORPREFERENCEON GLIMEPIRIDE+METFORMINAS A PARTOF PRELAUNCHACTIVITYAT MEDPAARPHARMACEUTICALS,,fTOM5.NDCCCMbCT,2OT3tO 15.h April,2014, Duringhistenureof internship,we found him sincereand hardworking.We wish him all the bestfor future endeavors. ForMedpaarPharmaceuticals,Ahmedabad
  4. 4. CERTIFICATE This is to certify that Mr. AMITSINH VIHOL, Reg. No. 1214MBAP19043, is a student of final year MBA[Pharma] and has submitted the project report titled “MARKET SURVEY OF DOCTOR PREFERENCE ON GLIMEPIRIDE + METFORMIN AS A PART OF PRELAUNCH ACTIVITY AT MEDPAAR PHARMACEUTICALS”, in partial fulfillment of the requirements for the award of the degree of Master of Business Administration [Pharma] during the academic year 2012-14. Coordinator, Dean, Mrs. Mallika Babu Dr. Gaurang B.Shah [M.Sc., MBA] [Ph.D., CCA] Department of Pharmaceutical Management, Pharmaceutical Sciences, KSV University, Gandhinagar. KSV University, Gandhinagar.
  5. 5. GUIDE CERTIFICATE This is to certify that the project report titled “MARKET SURVEY OF DOCTOR PREFERENCE ON GLIMEPIRIDE + METFORMIN AS A PART OF PRELAUNCH ACTIVITY AT MEDPAAR PHARMACEUTICALS”, submitted for fulfillment of the requirement for the award of the Degree of Master of Business Administration [Pharma], is the bonafide work of “Mr. AMITSINH VIHOL” who carried out the project work under my supervision. CO-GUIDE GUIDE Mr. CHARMING A. VAKIL Dr. SHRIKALP S. DESHPANDE [B.Pharm.; MBA Pharma] [Ph.D.;M.Pharm,] Department of Pharmaceutical Management, Department of Pharmaceutical Science, KSV University,Gandhinagar. KSV University,Gandhinagar.
  6. 6. Student Declaration I hereby declare that the thesis titled “Market Survey of Doctor Preference on Glimepiride + Metformin as a Part of Prelaunch Activity at Medpaar Pharmaceuticals” submitted to Kadi Sarva Vishwa Vidyalaya in fulfillment of the requirement for the award of the Degree of Master of Business Administration [Pharma] with Marketing/HR Specialisation is a record of project done by me under the guidance of Dr. Shrikalp Deshpande, Department of Pharmaceutical Science, KSV University, Gandhinagar & Mr. Charming A. Vakil, Department of Pharmaceutical Management, KSV University, Gandhinagar. It also assures that this work is original and no part of this report has been submitted for the award of any other degree/diploma/fellowship or similar titles or prizes. Place:Gandhinagar Date: Amitsinh Vihol
  7. 7. Pagei ACKNOWLEDGEMENT Every project big or small is successful largely due to the effort of a number of wonderful people who have always given their valuable advice or lent a helping hand. I sincerely appreciate the inspiration; support and guidance of all those people who have been instrumental in making this project a success. I, Amitsinh Vihol, the student of KSV MBA PHARMA GANDHINAGAR, am extremely grateful to “MEDPAAR PHARMACEUTICALS” for the confidence bestowed in me and entrusting my project entitled “Market Survey Of Doctor Preference On Glimepiride + Metformin As A Part Of Prelaunch Activity At Medpaar Pharmaceuticals” with special reference to Medpaar Pharmaceuticals. At this juncture I feel deeply honored in expressing my sincere thanks to Mr. Vilesh Patel (GM, Medpaar Pharmaceuticals) for making the resources available at right time and providing valuable insights leading to the successful completion of my project. I express my gratitude to Dr. Gaurang. B. Shah (Dean, KSV MBA Pharma) for arranging the major project in good schedule. I also extend my gratitude to my Project Guide Dr. Shrikalp Deshpande (Guide, HOD Pharmacology Depart., KBIPER) and Mr. Charming A. Vakil (Co-guide, Faculty at KSV MBA Pharma), who assisted me in compiling the project. I would also like to thank Mrs. Mallika Babu (Co-ordinator, KSV MBA Pharma), Mr. Hardik N. Patel (Faculty at KSV MBA Pharma) and Mr. Naresh Poturaju (Faculty at KSV MBA Pharma) for their critical advice and guidance without which this project would not have been possible. Last but not the least I place a deep sense of gratitude to my parents, family members and my friends who have been constant source of inspiration during the preparation of this project work. Amitsinh Vihol
  8. 8. Pageii ABSTRACT Glimepiride and Metformin combination is generally prescribed to the diabetic patient. In order to achieve the objectives a survey of Doctors (Physicians, General Practitioners) was conducted. Exploratory research was carried out. Aim of the study was to study doctor preference on Glimepiride-Metformin combination, to analyze the future market demand of this combination, to find out the mostly prescribed strength of this combination, to know which brand of this combination is superior in doctors and to analyze the brand and company selection criteria for this combination. In Data collection sources, Primary data were obtained from the field survey of 120 doctors which included Physicians and General Practitioners by using Convenience Sampling technique from North Gujarat Region (Mehsana, Himatnagar,Visnagar, Vijapur). And secondary data were gathered from books and Internet. Data was obtained on the basis of questionnaire filled and personal interview with the doctors. Data analysis of survey gave the interpretation that generally doctors prescribe Glimepiride and/or Metformin in diabetes mellitus because of maximum therapeutic effect and rapid action. According to survey Zoryl (Intas-23.8%), Glycomet Gp (USV-23.8%), Gemer (Sun-19%) and Gluconorm G (Lupin-13.3%) are mostly prescribed brands for Glimepiride and Metformin combination. About 73% doctors prescribe Glimepiride-1mg+Metformin-500mg. During survey it was found that this combination have side effects like hypoglycemia and stomach pain. Future Demand of Glimepiride+Metformin is high as per doctors’ opinion.
  9. 9. Pageiii Doctors find regular MR visit, scientific literature and samples for company selection. According to doctors, company image, effectiveness and price are most considerable factors for brand selection of Glimepiride+Metformin. From this study we concluded that most doctors preferred Glimepiride+Metformin for diabetes mellitus as a combination therapy in the strength of Glimepiride-1mg+Metformin-500mg. Company image, effectiveness and price are most considerable factors for brand selection.
  10. 10. Pageiv INDEX CHAPTER TITLE PAGE NO. NO. ACKNOWLEDGEMENT i ABSTRACT ii INDEX iv LIST OF TABLE vii LIST OF FIGURES viii LIST OF ABBREVIATION ix 1. INTRODUCTION 1 1.1 Market Overview 1 1.2 Trends and Developments 2 1.3 Key Issues 3 1.3.1 Hospitals 3 1.3.2 Insurance 3 1.3.3 Pharmaceuticals 3 1.3.4 Government 4 1.4 New Market 5 1.4.1 Diabetes Market 5 1.4.2 Thrombosis Market 8 2. COMPANY PROFILE 9 2.1 Introduction 9 2.2 Company Profile 9 2.3 Company Vision 10 2.4 Company Mission 10 2.5Core Values 11 2.6 Working Strategy 11
  11. 11. Pagev 2.7 Our Team 11 2.8 Product Portfolio 12 3. LITERATURE REVIEW 14 3.1 Type 1 Diabetes 14 3.2 Type 2 Diabetes 14 3.3 Impaired Fasting Glucose 15 3.4 Treatment 15 4. RESEARCH METHODOLOGY 18 4.1 Plan of Work 18 4.2 Research Objective 18 4.3 Scope of Study 19 4.4 Research Methodology and Design 19 4.5 Data Collection Source 19 4.6 Data Collection and Analysis 19 4.7 Limitation 20 5. DATA ANALYSIS 21 5.1 Demographic Characteristics 21 5.2 Patient Consulting During a Day 22 5.3 Consulting Diabetic Patient during a Day 23 5.4 Mostly Prescribe Drug for Type-2 Diabetic Mellitus 24 5.5 Reason for Prescribing Glimepiride+Metformin Combination 26 5.6 More Prefer Brand for Glimepiride+Metformin: 27 5.7 Most Prescribing Strength of Gllimepiride+Metformin 29 5.8 Adverse Reaction with Glimepiride+Metformin 31 5.9 Opinion on Future Demand of Glimepiride+Metformin 32 5.10 Preference to Select Company 33 5.10.1 Regular visit of Medical Representative 33 5.10.2 Samples 34
  12. 12. Pagevi 5.10.3 Knowledge Update Program by the Company 35 5.10.4 Scientific literature provided by company 36 5.10.5 Scientific support from company 37 5.10.11 All criteria for selection of company 38 5.11 Considering Factors for Brand Selection 40 5.11.1 Price 40 5.11.2 Company image 41 5.11.3 Availability 42 5.11.4 Effectiveness 43 5.11.5 Unique Tablet formulation 44 5.11.6 Overall preference for selection of Glimepiride+Metformin brand 45 6. FINDINGS 46 7. CONCLUSION 47 8. SUGGESTIONS 48 9. REFERENCE 49 10. APPENDIX 51
  13. 13. Pagevii LIST OF TABLE TABLE NO. NAME OF TABLE PAGE NO. 1.1 Indian Therapeutic Market 5 4.1 Plan of Work 18 5.1 Patient Consulting during a Day 22 5.2 Consulting Diabetic Patient during a Day 23 5.3 Mostly Prescribe Drug for Type 2 Diabetes 24 5.4 Reason for Prescribing Gllimepiride+Metformin Combination 26 5.5 More Prefer Brandfor Gllimepiride+Metformin 27 5.6 Most Prescribing Strength of Gllimepiride+Metformin 29 5.7 Adverse Reaction with Gllimepiride+Metformin 31 5.8 Opinion on Future Demand 32 5.9 Preference to Select Company-Regular Visit of MR 33 5.10 Preference to Select Company-Samples 34 5.11 Preference to Select Company-Knowledge Update Program 35 5.12 Preference to Select Company-Scientific Literature by Company 36 5.13 Preference to Select Company-Scientific Support from Company 37 5.14 Overall Preference for Selection of Company 38 5.15 Brand Selection-Price 40 5.16 Brand Selection-Company Image 41 5.17 Brand Selection-Availability 42 5.18 Brand Selection-Effectiveness 43 5.19 Brand Selection-Unique Tablet Formulation 44 5.20 Overall Preference for Brand Selection 45
  14. 14. Pageviii LIST OF FIGURES FIGURE NO. NAME OF FIGURE PAGE NO. 5.1 Sample Distribution (Areawise) 21 5.2 Sample Distribution (Genderwise) 21 5. 3 Sample Distribution (Agewise) 21 5.4 Patient Consulting during a Day 22 5.5 Consulting Diabetic Patient during a Day 23 5.6 Mostly Prescribe Drug for Type 2 Diabetes 24 5.7 Reason for Prescribing Gllimepiride+Metformin Combination 26 5.8 More Prefer Brandfor Gllimepiride+Metformin 27 5.9 Most Prescribing Strength of Gllimepiride+Metformin 29 5.10 Adverse Reaction with Gllimepiride+Metformin 31 5.11 Opinion on Future Demand 32 5.12 Preference to Select Company-Regular Visit of MR 33 5.13 Preference to Select Company-Samples 34 5.14 Preference to Select Company-Knowledge Update Program 35 5.15 Preference to Select Company-Scientific Literature by Company 36 5.16 Preference to Select Company-Scientific Support from Company 37 5.17 Overall Preference for Selection of Company 38 5.18 Brand Selection-Price 40 5.19 Brand Selection-Company Image 41 5.20 Brand Selection-Availability 42 5.21 Brand Selection-Effectiveness 43 5.22 Brand Selection-Unique Tablet Formulation 44 5.23 Overall Preference for Brand Selection 45
  15. 15. Pageix LIST OF ABBREVIATIONS CAGR- Compound Annual Growth Rate GDP- Gross Domestic Product CVD – Cardio Vascular Disease DCGI- Drugs Controller General of India GAD- Glutamic Acid Decarboxylase IFG- Impaired fasting glucose GP- General Practitioner MR- Medical Representative
  16. 16. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page1 CHAPTER 1: INTRODUCTION India with over 63 million diabetics represents the world’s second largest diabetes population after China. The Indian population that had faced under nutrition for a long time is now exposed to over nutrition and sedentary lifestyles. Coupled with a bad nutritional history and the fact that Indians are genetically more vulnerable to diabetes compared to other population groups, India’s struggle with diabetes is expected to be one of the biggest epidemics the country has ever witnessed. India’s diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine. Fuelled by a continuous increase in the healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country. This is creating lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined. 1.1 Market Overview In recent years, healthcare has become a priority for many countries, and India is no exception. The rapid development of technology, diagnostic equipment and treatments, coupled with people living longer and requiring more medical support with age, is a reality. With a population of more than 1.2 billion people, the Indian pharmaceutical market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 15.1% (±4.0%) between 2011 and 2016, reaching USD23.3 billion by 2016 (IMS Market Prognosis 2012). And as India’s economy continues to develop, the government is starting to prioritize its healthcare sector.
  17. 17.  INTRODUCTION  CHAPTER 1 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page2 1.2 Trends and developments As India moves towards its vision of improving access to basic healthcare, increasing the availability of free essential medicines, broadening basic health insurance coverage and boosting overall healthcare standards, several trends have emerged:  Expansion of Private Hospital Sector Private healthcare access is no longer limited to major metros, tier-I cities and prominent urban areas.  Imposition of Price Controls In a bid to regulate the prices of medicine, the government will be imposing broader direct price controls and a market-based regulation will be applied to all 348 drugs on the National List of Essential Medicines.  Issuance of Compulsory Licenses The government aims to extend the sphere of patent protection to the areas of pharmaceuticals, especially following the issuance of India’s first compulsory license in March 2012.  Growth of Promotional Tie-Ups To aid in market penetration, Indian pharmaceuticals companies have seen an increase in the number of promotional tie-ups between foreign and domestic businesses.
  18. 18.  INTRODUCTION  CHAPTER 1 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page3 1.3 Key Issues As India gears towards a new future in healthcare, hospitals, pharmaceuticals companies, insurance firms and the Indian government are hard pressed to address the issues prevalent in each sector. 1.3.1 Hospitals Over the years, sustained economic growth in India has fuelled a rising demand for quality care, driving rapid expansion of the hospital sector. In line with the government’s vision of making healthcare more accessible, India continues to see a growth in the number and capabilities of both public and private hospital and specialist clinic sectors. 1.3.2 Insurance The continued growth and expansion of India’s population and economy has driven the demand for, and development of, a burgeoning insurance industry. Intense competition, inadequate fraud detection systems and product innovation are critical challenges that must be addressed in order to secure longevity and profitability in this market. 1.3.3 Pharmaceuticals The pharmaceutical industry in India has taken a quantum leap with the rise in incomes, higher literacy rates and increased consumer awareness. Local firms and multinationals alike are challenged with identifying strategic new opportunities, efficiently reaching their target market, and anticipating critical competitive forces. The pharmaceutical industry in India has taken a quantum leap with the rise in incomes, higher literacy rates and increasing consumer awareness.
  19. 19.  INTRODUCTION  CHAPTER 1 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page4 Local firms and multinationals alike are challenged with identifying strategic new opportunities, efficiently reaching their target market, and anticipating the consequences of critical trends, including: • Tightening government regulations, leading to a more stable regulatory environment for companies. • Increasing resources devoted to local brand building • Broadening geographic coverage These trends and developments are combining to form a remarkably new landscape for pharmaceuticals companies to navigate as they work to create - and validate - sustainable strategies. 1.3.4 Government In recent years, the government has pushed addressing the lack of access to adequate, quality, public healthcare to the top of its agenda, and has committed to creating a standard that is on par with healthcare systems in developed countries. With the rising incidence of chronic diseases, the challenge of ensuring an effective utilization and distribution of India’s healthcare budget is more imperative than ever. In recent years, the government has pushed addressing the lack of access to adequate, quality, public healthcare to the top of its agenda, and has committed to creating a standard that is on par with healthcare systems benchmarked in developed countries. Currently, healthcare spending remains low at 4.2% of GDP, but rising patient incomes and the government’s overall commitment to boost funding for the improvement and expansion of the public health infrastructure will push this spending up significantly in the coming years.
  20. 20.  INTRODUCTION  CHAPTER 1 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page5 1.4 New Markets The increasing influence of the Western culture has seen many young Indians starting to adopt the lifestyle, especially in their food choices. As a result of this, while communicable diseases continue to take a heavy toll, chronic diseases such as cancer, diabetes, cardiovascular diseases and stroke are becoming increasingly prevalent. 1.4.1 Diabetes Market[7][9][10][11] The increasing rates of obesity and an aging population will increase the proportion of Indians who are diabetic; by 2016 the market is estimated to be worth USD 1.76 billion. (IMS Market Prognosis 2012). Table 1.1 Indian Therapeutic Market[10] SUPERGROUP MAT VAL IN CRS MAT VAL GR JAN-14 MONTH JAN-14 MONTH GR IPM 74452.2 5.8 6232.6 8.6 ANTI-INFECTIVES 12559.5 0.6 964.9 1.3 CARDIAC 9240.4 8.6 823.2 8.8 GASTRO INTESTINAL 8406.9 5.4 674.3 9.9 VITAMINS / MINERALS / NUTRIENTS 6592.8 4.8 531.2 10.9 RESPIRATORY 5848.1 9.1 543.7 9.8 PAIN / ANALGESICS 5363.6 3.7 428.7 5.8 ANTI DIABETIC 5209.1 14.8 481.5 19.1 NEURO / CNS 4674.1 8.1 410.4 8.5 GYNAECOLOGICAL 4653.3 2.2 383.9 1.8 DERMA 4068.8 10.4 350.3 16.0 OPHTHAL / OTOLOGICALS 1352.0 9.0 110.8 12.4 HORMONES 1257.4 5.4 106.2 7.5 VACCINES 1087.3 -4.3 85.7 -3.3 ANTI-NEOPLASTICS 977.5 21.1 85.2 37.0 OTHERS 912.6 1.9 82.2 18.3 BLOOD RELATED 882.5 2.1 72.1 9.2 ANTI MALARIALS 611.8 0.9 31.2 10.0 SEX STIMULANTS / REJUVENATORS 420.2 5.1 39.0 8.6 STOMATOLOGICALS 334.1 7.5 28.0 9.7 (Express-Pharma-financial, 2014)
  21. 21.  INTRODUCTION  CHAPTER 1 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page6 The Credit Suisse report on speciality pharmaceuticals said Sun Pharma, Glenmark and Lupin have the best overall portfolios in India. Glenmark gets only one-fourth of its sales from chronic therapies and despite that it has the highest exposure in the fastest-growing molecules. Sun Pharma too has strong exposure to high-growth molecules and consistently gained market share across the segments. Lupin and Glenmark also continued to gain market shares in the highest growth segment. Among other leading pharma players, Dr Reddy's, Cadila and Cipla have high exposure to slow-growing molecules. According to the report, Dr Reddy's, Cipla and Cadila have almost 60 percent of sales coming from molecules growing less than 15 percent, which explains weak India sales growth for these firms, while leaders like Dr Reddy's and Ranbaxy slipped on growth trajectory in last two years due to market share loss. India has seen the entry of more drugs to tap the fast growing market for diabetes. Global major - Novo Nordisk and domestic leaders – Lupin, Sun pharma, Glenmark, Zydus Cadila, Piramal Enterprises, Emcure Pharma are gearing up with new products, as well as division launches, to grab a bigger pie. The country, which has about 65 million diabetics, will see the number grow to 100 million by 2030. Hence, the market is expected to reach Rs 6,500 crore by 2015 from the current size Rs 4,500 crore, a growth of 45 per cent. Novo Nordisk launched Tresiba, a new basalinsulin for patients with type-I and type-II diabetes. The company claimed this would offer flexibility in the timing of insulin administration.
  22. 22.  INTRODUCTION  CHAPTER 1 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page7 Apart from nearly 65 million diabetics, India has 77 million pre-diabetics. About 85-90 per cent of the patients suffer from dyslipidemia or lipid abnormalities, causing cardiovascular diseases (CVD). In India, one of every five persons is at serious risk of developing cardiovascular diseases. It is second to China in number of diabetics across the globe. Genetically, Indians become diabetic much earlier than their western counterparts. Nowadays, even children at age of 13-14 are diabetics due to the change in lifestyles – consumption of junk food, fast food and growing obesity. Though the market is crowded with drugs for diabetics, drugs with novel technologies are hitting the market nowadays. Molecules for diabetes act on different pathways where drug metabolism is changed. One molecule which acts on one may not work on another patient. This creates enough room for each new drug in India. Piramal’s molecule- P7435 has been developed by the NCE Research Division of PEL for the management of metabolic disorders such as lipid abnormalities and diabetes. Zydus Cadila has developed a new class of diabetic drug Saroglitazar, branded as Lipaglyn and received marketing approval from the Drugs Controller General of India (DCGI) in June. According to Cadila claims, Lipaglyn is the world’s first drug for treating diabetic dyslipidemia combining lipid and glucose lowering effects in one single molecule. Diabetic Dyslipidemia is a condition where a person is diabetic and has elevated levels of the total cholesterol. Recently, Pune-based Emcure has ventured into diabetic segment by launching Criante, a new diabetic care division.
  23. 23.  INTRODUCTION  CHAPTER 1 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page8 1.4.2 Thrombosis Market With government and industry initiatives working to broaden access to treatment in India, the introduction and increased availability of anti-thrombotic drugs is expected to expand exponentially and could be worth USD$272 million by 2016 (IMS Market Prognosis 2012).
  24. 24. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page9 CHAPTER 2: COMPANY PROFILE 2.1 Introduction Established in the year 2010, we, “Medpaar Pharmaceuticals”, are counted amongst the prominent suppliers of an extensive range of Health Care Products. Our range of Health Care Products provides cure to various ailments and appreciated for its purity, accurate composition & long shelf life. Moreover, our research and development experts keep them updated with prevailing market trends and conduct various market survey to ensure that our products are reasonable prices in the national market. With the support of our well-connected transportation network, we have been able to ensure the timely delivery of the consignments at the clients' site. All these attributes have enabled us in acquiring certificate of registration under Gujarat value added tax act, 2003 and license to manufacture for sale drugs. Our owner, 'Mr. Vilesh Patel', holds wide industry experience in the field of pharmaceutical sector. His excellent administration skills and profound knowledge has guides us in every sphere of business. Under his able guidance, we have been able to gain a respectable position of ourselves in this highly competitive industry. 2.2 Company Profile Business Type •Marketer & Supplier Ownership & Capital Year of Establishment •2008 Ownership Type •Partnership Firm Trade & Market Annual Turnover •Rs. 10-12 million Approx Total Number of Employees •25 People Company USP •Provide After Sales Support
  25. 25.  COMPANY PROFILE  CHAPTER 2 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page10 Primary Competitive Advantage •Good Financial Position & TQM •Good Product Line Payment Mode •Cash •Cheque •Credit Card •DD 2.3 Company Vision “We will endeavor to emerge as a leader in the integrated pharmaceuticals business by continually achieving and surpassing the highest standards in quality". At Medpaar, we will continuously provide value to all stakeholders of the organization with a focus on innovation and core values towards achieving excellence across all operations. 2.4 Company Mission  Our determined commitment to our values in integrity, transparency and responsible corporate citizenship along all facets of our value chain  A continuous focus on achieving excellence and leadership through the highest standards of quality across all functions of our organization  Ensuring a safe and healthy environment for all personnel and maintaining harmony with the natural environment  Recruiting, training and retain the highest caliber of professionals in the industry  To ensure the well-being of the community by effectively fulfilling social responsibilities
  26. 26.  COMPANY PROFILE  CHAPTER 2 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page11 2.5 Core Values “Medpaar Pharmaceuticals is an integrity driven organization that focuses on traditional values coupled with innovative management". Our core values are defined as follows:  To Inspire trust through example driven Leadership across all aspects of the management of our company  To pursue excellence through a continual focus on quality and innovation  To emerge as an employer of choice through the best human resource practices and continuously invest in human capital over the longer term 2.6 Working Strategy Being a trusted name in the sphere of Health Care Products, we pay immense attention towards operations, financial stability, growth, market position and long- term success. From hospital strategy to physician alignment, we assist you in each and every aspect. In this regard, we have appointed a team of professionals, which is highly experienced & committed towards providing our clients with efficient solutions. It is due to our client-centric approach that we have been able to implement the plan in the following areas: • Co-Management physician acquisition • Alternatives to physician employment • Practice management • Physician manpower planning • Physician compensation 2.7 Our Team We are supported by a dexterous team of professionals, which is highly skilled and plays a pivotal role in the consistent growth of our organization. Our
  27. 27.  COMPANY PROFILE  CHAPTER 2 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page12 professionals possess wide industry experience in this domain due to which, we have been able to provide continuous improvisation in our range. In our team, we have following professionals: • Medical experts • Pharmacists • Marketing Experts All these professionals work in harmony with each. They also undergo skill enhancing training on regular basis to keep them updated with latest market changes and industrial standards, so as to be ahead of times. 2.8 Product Portfolio We are a supplier of a comprehensive range of Health Care Products for human purposes. It is hygienically processed using active ingredients and used for the treatment of various ailments. Health Care Products offered by us are in compliance with set industry standards and highly demanded by leading customers based in pharmaceutical & health care sectors. 2.9 Company product range: 1. Folcymed Tab. 2. Folcymed Z Tab. 3. Calcitar 500 Tab. 4. Laximed Solution 5. Rabidem 20 Tab. 6. Rabidem DSR Cap. 7. Pantodem 40 Tab. 8. Pantodem D Tab. 9. Pantodem DSR Cap. 10.Meditus Tab.
  28. 28.  COMPANY PROFILE  CHAPTER 2 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page13 11.Meditus Cough Syrup 12.Bro-Medex Expectorant 13.Medex Cough Syrup 14.Cefidem 200 DT 15.Safepod DT 16.Safepod Dry Syrup 17.Azidem 250 Tab. 18.Azidem 500 Tab. 19.Flucodem 150 Tab. 20.Levodem 250 Tab. 21.Levodem 500 Tab. 22.Oflodem OZ Tab. 23.Medpar Tab. 24.Medpar SP Tab. 25.Medpar Plus Tab. 26.Medcort Tab. 27.Medcort Suspension 28.Medmarin Suspension 29.Anxypar-0.25 Tab.
  29. 29. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page13 CHAPTER 3: REVIEW OF LITERATURE Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Several pathogenic processes are involved in the development of diabetes. These range from autoimmune destruction of the β-cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action of insulin on target tissues. Deficient insulin action results from inadequate insulin secretion and/or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action. Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient, and it is often unclear which abnormality, if either alone, is the primary cause of the hyperglycemia. Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision. Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia. Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis or the nonketotic hyperosmolar syndrome. Long-term complications of diabetes include retinopathy with potential loss of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot ulcers, amputations, and Charcot joints; and autonomic neuropathy causing gastrointestinal, genitourinary, and cardiovascular symptoms and sexual dysfunction. Patients with diabetes have an increased incidence of atherosclerotic cardiovascular, peripheral arterial, and cerebrovascular disease. Hypertension and abnormalities of lipoprotein metabolism are often found in people with diabetes.
  30. 30.  REVIEW OF LITERATURE  CHAPTER 3 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page14 3.1 Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) Immune-mediated diabetes[2][18][19] This form of diabetes, which accounts for only 5–10% of those with diabetes, previously encompassed by the terms insulin-dependent diabetes, type I diabetes, or juvenile-onset diabetes, results from a cellular-mediated autoimmune destruction of the β-cells of the pancreas. Markers of the immune destruction of the β-cell include islet cell autoantibodies, autoantibodies to insulin, autoantibodies to glutamic acid decarboxylase (GAD65), and autoantibodies to the tyrosine phosphatases IA-2 and IA-2β. One and usually more of these autoantibodies are present in 85–90% of individuals when fasting hyperglycemia is initially detected. In this form of diabetes, the rate of β-cell destruction is quite variable, being rapid in some individuals (mainly infants and children) and slow in others (mainly adults). Some patients, particularly children and adolescents, may present with ketoacidosis as the first manifestation of the disease. Others have modest fasting hyperglycemia that can rapidly change to severe hyperglycemia and/or ketoacidosis in the presence of infection or other stress. Still others, particularly adults, may retain residual β-cell function sufficient to prevent ketoacidosis for many years; such individuals eventually become dependent on insulin for survival and are at risk for ketoacidosis. At this latter stage of the disease, there is little or no insulin secretion, as manifested by low or undetectable levels of plasma C-peptide. Immune-mediated diabetes commonly occurs in childhood and adolescence, but it can occur at any age, even in the 8th and 9th decades of life. 3.2 Type 2 diabetes (ranging from predominantly insulin resistance with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance) [2][18][19] This form of diabetes, which accounts for ∼90–95% of those with diabetes, previously referred to as non-insulin-dependent diabetes, type II diabetes, or adult- onset diabetes, encompasses individuals who have insulin resistance and usually have relative (rather than absolute) insulin deficiency At least initially, and often throughout their lifetime, these individuals do not need insulin treatment to survive. There are probably many different causes of this form of diabetes. Although the
  31. 31.  REVIEW OF LITERATURE  CHAPTER 3 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page15 specific etiologies are not known, autoimmune destruction of β-cells does not occur, and patients do not have any of the other causes of diabetes. 3.3 Impaired fasting glucose (IFG)[2][18][19] The Expert Committee (1,2) recognized an intermediate group of subjects whose glucose levels, although not meeting criteria for diabetes, are nevertheless too high to be considered normal. This group is defined as having fasting plasma glucose (FPG) levels ≥100 mg/dl (5.6 mmol/l) but <126 mg/dl (7.0 mmol/l) Thus, the categories of FPG values are as follows: FPG <100 mg/dl (5.6 mmol/l) = normal fasting glucose; FPG 100–125 mg/dl (5.6–6.9 mmol/l) = IFG (impaired fasting glucose); FPG ≥126 mg/dl (7.0 mmol/l) = provisional diagnosis of diabetes (the diagnosis must be confirmed) 3.4 Treatment[8][12][13] Type 2 diabetes mellitus, a disorder of impaired insulin secretion and insulin resistance, has reached epidemic proportions. The effective management of Type 2 diabetes is of vital concern to clinicians. The identification of high-risk individuals and lifestyle management can help control diabetes; however, most patients require pharmacologic intervention. The goals of pharmacologic therapy are to achieve adequate glycemic control while avoiding hypoglycemia and weight gain and to minimize the risk of future micro- and macrovascular complications. There are a number of available glucose-lowering agents from which to choose. Sometimes blood sugar levels remain high in people with type 2 diabetes even though they eat in a healthy manner and exercise. When this happens, medications may be prescribed. The medications work in several different ways. These include improve the effectiveness of the body's natural insulin, reduce blood sugar production, increase insulin production and inhibit blood sugar absorption. Some of the most common types of medication are listed below. They are taken by mouth or injection.
  32. 32.  REVIEW OF LITERATURE  CHAPTER 3 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page16 Alpha-glucosidase inhibitors Biguanides DPP IV inhibitors Injectable medicines Meglitinides Sulfonylureas Thiazolidinediones The sulfonylureas, the first oral agents introduced for the management of Type 2 diabetes, which are effective, well-tolerated, and well-established drugs, Second-generation sulfonylureas are now widely used in the management of Type 2 diabetes. The most recent addition, glimepiride, can be used in combination with metformin, the thiazolidinediones, α-glucosidase inhibitors, and insulin. Glimepiride achieved desirable glycemic control in patients with recent-onset type 2 DM through improvement in insulin secretion and sensitivity. (Kabadi, Mary U.; Kabadi, Udaya, 2014). The unique properties of glimepiride may provide advantages over other currently available insulin secretagogues. Insulin resistance occurs early in type 2 diabetes disease process and may lead to progressive beta cell failure and overt diabetes (Abdul-Ghani, Tripathy, & DeFronzo, 2006). Monotherapy can slow down but does not prevent the progression of the disease. Successful management requires combination therapy that addresses both insulin resistance and beta cell dysfunction (Cefalu, Waldman, & Ryder, 2007). Clinical trials support the use of combinations of antidiabetic agents with complementary mechanisms of action such as ansulfonylurea/metformin (Dailey, 2003; Rendell, 2004). Metformin and glimepiride seem to be particularly well suited for use in combination because of their different mechanisms of action. Metformin inhibits hepatic glucose production and increases the sensitivity of peripheral tissues to insulin, whereas glimepiride works primarily to increase insulin secretion. These drugs appear to have complementary effects in improving glycemic control, as well as beneficial effects on lipids and body weight (DeFronzo & Goodman, 1995). In one clinical trial of 372 patients, the combination of glimepiride and metformin was
  33. 33.  REVIEW OF LITERATURE  CHAPTER 3 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page17 significantly more effective than either drug alone in reducing A1C concentration or glucose and PPG levels (Charpentier et al., 2001). On one hand, glibenclamide+metformin is the oral antidiabetic combination most used in the clinical practice today (Dailey, 2003); on the other hand, Glimepiride considered as a third-generation sulfonylurea agent--has several beneficial pharmacological effects over glibenclamide, a second-generation sulfonylurea. Glimepiride combined with metformin in a single dose presentation has proved to be effective and safe for type 2 diabetes patients who fail with monotherapy on oral antidiabetic agents (González-Ortiz, Martínez-Abundis, & Grupo para el tratamiento de la diabetes mellitus con combinaciones, 2004). Glimepiride+metformin showed a greater efficacy in reaching the metabolic goal of glycemic control with less hypoglycemic events in patients with uncontrolled type 2 diabetes mellitus in comparison with glibenclamide+metformin. (González- Ortiz, Nov 2009) In long term diabetes treatment higher doses of insulin and combined therapy with insulin and metformin may be more beneficial than with low doses of insulin or sulfonyl urea alone (Sona Valsara, 2009)
  34. 34. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page18 CHAPTER: 4 RESEARCH METHODOLOGY 4.1 Plan of Work Table 4.1 PLAN OF WORK 4.2 Research objective:-  To study doctor perception on Glimepiride+Metformin.  To analyze brand selection criteria for Glimepiride+Metformin.  To determine which brand is superior according to doctor.  To analyze the future market demand of Glimepiride+Metformin.  To determine which strength Glimepiride+Metformin is mostly use. DATE ACTIVITY 05/12/2013 To 20/01/2014 Medpaar Pharmaceuticals Visit Selection of project title Secondary research on internet and questionnaire formation 23/01/2014 ITD presentation 01/02/2014 Initial survey. 05/03/2014 Survey completion. 07/03/2014 Surveys are reported. 10/03/2014 To 12/03/2014 Complete theoretical portion of the project. 15/03/2014 To 20/03/2014 Data interpretation and analysis. 21/03/2014 To 23/03/2014 Finding and conclusion. 11/04/2014 Finishing project.
  35. 35.  RESEARCH METHODOLOGY  CHAPTER 4 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page19 4.3 Scope of study:- As we described, I grab the opportunity to get the research work regarding satisfactory level among the doctors regarding new product launch for type-2 diabetic which contain Glimepiride and Metformin by Medpaar Pharmaceuticals. Therefore our scope of study is “the doctors’ preference on Glimepiride+Metformin as the part of pre-launching activity.” 4.4 Research Methodology and Design[15]  In order to achieve the objectives a survey of Doctors (Physicians, General Practitioners) was conducted.  Research Design: Exploratory research. 4.5 Data Collection Sources[15]  Primary Data:  Primary data is collected from fieldwork (by using questionnaire).  Target Population: Doctors (Physicians, General Practitioners)  Sampling Technique: Convenience Sampling.  Sample Size: Doctors- 105,  Sampling Area: North Gujarat Region.  Secondary Data:  Secondary data is gathered from internet and books. 4.6 Data Collection and Analysis[15]  Questionnaire was used to collect data from doctors.  Data was obtained on the basis of questionnaire filled and personal interview with the doctors.  The survey was conducted in various areas of North Gujarat(Mehsana, Himatnagar, Visnagar, Vijapur)  Data Analysis is done by SPSS and Microsoft Excel software in computer.
  36. 36.  RESEARCH METHODOLOGY  CHAPTER 4 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page20 4.7 Limitations  For the study non probability sampling was used and sample may not be a true representative of the universe.  Due to the time constraints, sample size was limited to 105 consumers, which may not be adequate for the generalization of the findings.  Study was carried out in North Gujarat region only so conclusion can’t be drawn for the whole state.  Unwillingness of doctors to give response.
  37. 37. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page21 CHAPTER 5: DATA ANALYSIS 5.1 Demographic Characteristics: Figure 5.1 SAMPLE DISTRIBUTION (AREA) Figure 5.2 SAMPLE DISTRIBUTION (GENDERWISE) Figure 5.3 SAMPLE DISTRIBUTION (AGEWISE) 34 12 8 20 11 8 2 10 0 5 10 15 20 25 30 35 40 MEHSANA VISNAGAR VIJAPUR HIMATNAGAR NO.OFDOCTORS PLACE SAMPLE DISTRIBUTION (AREA) MD GP 93% 7% GENDER MALE FEMALE 34% 66% 0%0% AGE 20-40 YEARS 40-60 YEARS ABOVE 60 YEARS
  38. 38.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page22 5.2 Patient Consulting During a Day: Table 5.1 RECOMANDED DATA (PATIENT CONSULTING DURING A DAY) Patient consulting during a day Frequency Percent Cumulative Percent 1 TO 20 21 TO 40 41 TO 60 61 TO 80 0 0 2 14 0.0 0.0 1.9 13.3 0.0 0.0 1.9 15.2 MOTE THAN 81 89 84.8 100.0 Total 100 100.0 Figure 5.4 RECOMANDED DATA ANALYSIS (PATIENT CONSULTING DURING A DAY) INTERPRETATION: During research it was found that in a day 84.8% of doctors are consulting more than 80 patients, 13.3% of doctors consulting 61 to 80 patients and 1.9% of doctors consulting 41 to 60 patients. 0 0 2 14 89 0 10 20 30 40 50 60 70 80 90 100 1 TO 20 21 TO 40 41 TO 60 61 TO 80 MOTE THAN 81 NO.OFDOCTORS NO. OF PATIENT PATIENT CONSULTING DURING A DAY NO. OF DOCTORS
  39. 39.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page23 5.3 Consulting Diabetic Patient during a Day: Table5.2 RECOMMANDED DATA (CONSULTING DIABETIC PATIENT DURING A DAY) CONSULTING DIABETIC PATIENT DURING A DAY Frequency Percent Cumulative Percent 1 TO 5 8 7.6 7.6 6 TO 10 21 20.0 27.6 11 TO 15 64 61.0 88.6 16 TO 20 7 6.7 95.2 MORE THAN 21 5 4.8 100.0 Total 100 100.0 Figure 5.5 RECOMMANDED DATA ANALYSIS (CONSULTING DIABETIC PATIENT DURING A DAY) INTERPRETATION: During research it was found that in a day 61% of doctors consults average 11-15 diabetic patients, 20% of doctors consult 6-10 diabetic patients, 7.6% of doctors consult 1-5 diabetic patients, 6.7% of doctors consult 16- 20 diabetic patients and 4.8% of doctors consult more than 21 diabetic patients. 8 21 64 7 5 0 10 20 30 40 50 60 70 1 TO 5 6 TO 10 11 TO 15 16 TO 20 MORE THAN 21 NO.OFDOCTORS NO. OF DIABETIC PATIENT CONSULTING DIABETIC PATIENT DURING A DAY NO. OF DOCTORS
  40. 40.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page24 5.4 Mostly Prescribe Drug For Type-2 Diabetic Mellitus: Table 5.3 RECOMMANDED DATA (MOSTLY PRESCRIBE DRUG FOR TYPE 2 DIABETES) MOSTLY PRESCRIBE DRUG FOR TYPE 2 DIABETES Frequency Percent Cumulative Percent GLIMEPIRIDE 29 27.6 27.6 METFORMIN 35 33.3 61.0 GLIMEPIRIDE+METFORMIN 17 16.2 77.1 PIOGLITAZONE 10 9.5 86.7 SITAGLIPTIN 2 1.9 88.6 OTHER 12 11.4 100.0 Total 105 100.0 Figure 5.6 RECOMMANDATION DATA ANALYSIS (MOSTLY PRESCRIBE DRUG FOR TYPE 2 DIABETES) GLIMEPIRIDE METFORMIN GLIMEPIRIDE+METFOR MIN PIOGLITAZONE SITAGLIPTIN OTHER MOSTLY PRESCRIBE DRUG FOR TYPE 2 DIABETES GLIMEPIRIDE METFORMIN GLIMEPIRIDE+METFORMIN PIOGLITAZONE SITAGLIPTIN OTHER
  41. 41.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page25 INTERPRETATION: During research it was found that 33.3% doctors prescribe Metformin, 27.6% doctors prescribe Glimepiride, 16.2% doctors prescribe Metformin + Glimepiride, 9.5% doctors prescribe Pioglitazone, 6.66% doctors prescribe Acarbose, 4.76% doctors prescribe Voglibose and 1.9% doctors prescribe Sitagliptin.
  42. 42.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page26 5.5 Reason For Prescribing Glimepiride+Metformin Combination: Table 5.4 RECOMMANDED DATA (REASON FOR PRESCRIBING GLLIMEPIRIDE+METFORMIN COMBINATION) REASON FOR PRESCRIBING GLLIMEPIRIDE+METFORMIN COMBINATION Frequency Percent Cumulative Percent MAXIMUM THERAPEUTIC EFFECT 88 83.8 83.8 RAPID ACTION 17 16.2 100.0 MINIMUM SIDE EFFECT 0 0.0 100.0 ALL THREE 0 0.0 100.0 Total 105 100.0 Figure 5.7 RECOMMANDED DATA ANALYSIS (REASON FOR PRESCRIBING GLLIMEPIRIDE+METFORMIN) INTERPRETATION: During research it was found that 83.8% doctors prescribe this combination because of maximum therapeutic effect, 16.2% doctors prescribe this combination because of rapid action. 88 17 0 0 0 10 20 30 40 50 60 70 80 90 100 MAXIMUM THERAPEUTIC EFFECT RAPID ACTION MINIMUM SIDE EFFECT ALL THREE NO.OFDOCTORS REASON FOR PRESCRIBING METFORMIN+GLIMEPIRIDE REASON FOR PRESCRIBING METFORMIN+GLIMEPIRIDE NO. OF DOCTORS
  43. 43.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page27 5.6 More Prefer Brand for Glimepiride+Metformin: Table 5.5 RECOMMANDED DATA (MORE PREFER BRANDFOR GLLIMEPIRIDE+METFORMIN) MORE PREFER BRAND FOR GLLIMEPIRIDE+METFORMIN Frequency Percent Cumulative Percent GLIMESTAR-M 7 6.7 6.7 GLIMY-M 6 5.7 12.4 GLISTA 3 2.9 15.2 GEMER 20 19.0 34.3 GLUCONORM-G 14 13.3 47.6 OTHERS (ZORYL, GLYCOMET GP, ZIGLIM) 55 (ZOR-25) (GLY-25) (ZIG-5) 52.4 (23.80) (23.80) (4.76) 100.0 Total 105 100.0 Figure 5.8 RECOMMANDED DATA ANALYSIS (MORE PREFER BRAND OF GLLIMEPIRIDE+METFORMIN) 7 6 3 20 14 55 0 10 20 30 40 50 60 NO.OFDOCTORS METFORMIN+GLIMEPIRIDE BRANDS MORE PREFER BRANDS OF METFORMIN+GLIMEPIRIDE NO. OF DOCTORS
  44. 44.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page28 INTERPRETATION: During research it was found that 52.4% doctors preferred other brands, 19% doctors preferred Gemer (Sun), 13.3% doctors preferred Gluconorm-G (Lupin), 6.7% doctors preferred Glimestsr-M (Mankind), 5.7% doctors preferred Glimy-M (Dr. Reddy) and 2.9% doctors preferred Glista (Cadila).
  45. 45.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page29 5.7 Most Prescribing Strength of Gllimepiride+Metformin: Table 5.6 RECOMMANDED DATA (MOST PRESCRIBING STRENGTH OF GLLIMEPIRIDE+METFORMIN) MOSTLY PRESCRIBE STRENGTH Frequency Percent Cumulative Percent GLIMEPIRIDE-1MG + METFORMIN-500MG 77 73.3 73.3 GLIMEPIRIDE-2MG+ METFORMIN-500MG 8 7.6 81.0 GLIMEPIRIDE-1MG + METFORMIN-1000MG 20 19.0 100.0 GLIMEPIRIDE-4MG + METFORMIN-1000MG 0 0.0 100.0 GLIMEPIRIDE-1MG + METFORMIN-850MG 0 0.0 100.0 Total 105 100.0 Figure 5.9 RECOMMANDED DATA ANALYSIS (MOST PRESCRIBING STRENGTH OF GLLIMEPIRIDE+METFORMIN) INTERPRETATION: During research it was found that 73.3% doctors prescribe Glimepiride-1mg+Metformin-500mg, 7.6% doctors prescribe Glimepiride- 2mg+Metformin-500mg and 19% doctors prescribe Glimepiride-1mg+Metformin- 77 8 20 0 0 0 10 20 30 40 50 60 70 80 90 GLIMEPIRIDE-1MG + METFORMIN-500MG GLIMEPIRIDE-2MG+ METFORMIN-500MG GLIMEPIRIDE-1MG + METFORMIN-1000MG GLIMEPIRIDE-4MG + METFORMIN-1000MG GLIMEPIRIDE-1MG + METFORMIN-850MG NO.OFDOCTORS PRESCRIBING STRENGTH PRESCRIBE STRENGTH OF METFORMIN+GLIMEPIRIDE NO. OF DOCTORS
  46. 46.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page30 1000mg.It is indicate the highest demand of Glimepiride-1mg+Metformin-500mg strength in the market.
  47. 47.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page31 5.8 Adverse Reaction with Glimepiride+Metformin: Table 5.7 RECOMMANDED DATA (ADVERSE REACTION WITH GLLIMEPIRIDE+METFORMIN) ADVERSE REACTION WITH GLLIMEPIRIDE+METFORMIN Frequency Percent Cumulative Percent YES 47 44.8 44.8 NO 58 55.2 100.0 Total 105 100.0 Figure 5.10 RECOMMANDED DATA ANALYSIS (ADVERSE REACTIONS WITH GLLIMEPIRIDE+METFORMIN) INTERPRETATION: During research it was found that 55.2% doctors have not find adverse reactions with this combination and 44.8% doctors find adverse reactions with this combination due to patient incompatibility with drug. Generally hypoglycemia & stomach pain occur in patient of type 2 diabetes as adverse reaction. 45% YES55% NO 0%0% ADVERSE REACTIONS WITH METFORMIN+GLIMEPIRIDE YES NO
  48. 48.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page32 5.9 Opinion on Future Demand of Glimepiride+Metformin: Table 5.8 RECOMMANDED DATA (OPINION ON FUTURE DEMAND) OPINION ON FUTURE DEMAND Frequency Percent Cumulative Percent VERY HIGH DEMAND 0 0.0 0.0 HIGH DEMAND 73 69.5 69.5 AVERAGE DEMAND 32 30.5 100.0 LOW DEMAND 0 0.0 100.0 VERY LOW DEMAND 0 0.0 100.0 Total 105 100.0 Figure 5.11 RECOMMANDED DATA ANALYSIS (OPINION ON FUTURE DEMAND) INTERPRETATION: During research it was found that 69.5% doctors have opinion to high future demand of this combination and 30.5% doctors have opinion to average demand of this combination. It is indicate chance to launch new brand of Glimepiride+Metformin due to high demand in future. 73 32 0 0 0 10 20 30 40 50 60 70 80 VERY HIGH DEMAND HIGH DEMAND AVERAGE DEMAND LOW DEMAND VERY LOW DEMAND NO.OFDOCTORS FUTURE DEMAND OPINION ON FUTURE DEMAND OF METFORMIN+GLIMEPIRIDE NO. OF DOCTORS
  49. 49.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page33 5.10 Preference to Select Company: 5.10.1 Regular visit of Medical Representative: Table 5.9 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-REGULAR VISIT OF MR) REGULAR VISIT OF MR Frequency Percent Cumulative Percent HIGHLY PREFERRED 95 90.5 90.5 PREFERRED 8 7.6 98.1 MODERATELY PREFERRED 2 1.9 100.0 LESS PREFERRED 0 0.0 100.0 NOT PREFERRED 0 0.0 100.0 Total 105 100.0 Figure 5.12 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-REGULAR VISIT OF MR) INTERPRETATION: During research it was found that 90.5% doctors highly prefers and 7.6% doctors prefers regular visit of MR for selection of company, 1.9% doctors moderately prefers regular visit of MR for selection of company. 95 8 2 0 0 0 10 20 30 40 50 60 70 80 90 100 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION REGULAR VISIT OF MR NO. OF DOCTORS
  50. 50.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page34 5.10.2 Samples: Table 5.10 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-SAMPLES) SAMPLES Frequency Percent Cumulative Percent HIGHLY PREFERRED 82 78.1 78.1 PREFERRED 13 12.4 90.5 MODERATELY PREFERRED 5 4.8 95.2 LESS PREFERRED 5 4.8 100.0 Total 105 100.0 Figure 5.13 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-SAMPLES) INTERPRETATION: During research it was found that 78.1% doctors highly prefer and 12.4% doctors prefer to consider samples for selection of company, 4.8% doctors moderately prefer samples while 4.8% doctors less prefer to consider samples for selection of company. 82 13 5 5 0 10 20 30 40 50 60 70 80 90 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION SAMPLES PROVIDED BY COMPANY NO. OF DOCTORS
  51. 51.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page35 5.10.3 Knowledge update program by the company: Table 5.11 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-KNOWLEDGE UPDATE PROGRAM) KNOWLEDGE UPDATE PROGRAM BY THE COMPANY Frequency Percent Cumulative Percent HIGHLY PREFERRED 76 72.4 72.4 PREFERRED 12 11.4 83.8 MODERATELY PREFERRED 11 10.5 94.3 LESS PREFERRED 6 5.7 100.0 Total 105 100.0 Figure 5.14 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-KNOWLEDGE UPDATE PROGRAM) INTERPRETATION: During research it was found that 72.4% doctors highly prefer and 11.4% doctors prefer to consider knowledge update program for selection of company, 10.5% doctors moderately prefer to consider knowledge update program for selection of company while 5.7% doctors less prefer to consider knowledge update program for selection of company. 76 12 11 6 0 0 10 20 30 40 50 60 70 80 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION KNOWLEDGE UPDATE PROGRAM BY THE COMPANY NO. OF DOCTORS
  52. 52.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page36 5.10.4 Scientific literature provided by company: Table 5.12 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-SCIENTIFIC LITERATURE BY COMPANY) SCIENTIFIC LITERATURE PROVIDED BY COMPANY Frequency Percent Cumulative Percent HIGHLY PREFERRED 80 76.2 76.2 PREFERRED 20 19.0 95.2 MODERATELY PREFERRED 3 2.9 98.1 LESS PREFERRED 2 1.9 100.0 NOT PREFERRED 0 0.0 100.0 Total 105 100.0 Figure 5.15 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-SCIENTIFIC LITERATURE BY COMPANY) INTERPRETATION: During research it was found that 76.2% doctors highly prefer and 19% doctors prefer to consider scientific literature provided by company for selection of brand, 2.9% doctors moderately preferred to consider scientific literature provided by company for selection of brand while 1.9% doctors less prefer to consider scientific literature for selection of company. 80 20 3 2 0 0 10 20 30 40 50 60 70 80 90 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION SCIENTIFIC LITERATURE PROVIDED BY COMPANY NO. OF DOCTORS
  53. 53.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page37 5.10.5 Scientific support from company: Table 5.13 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-SCIENTIFIC SUPPORT FROM COMPANY) SCIENTIFIC SUPPORT FROM COMPANY Frequency Percent Cumulative Percent HIGHLY PREFERRED 61 58.1 58.1 PREFERRED 24 22.9 81.0 MODERATELY PREFERRED 15 14.3 95.2 LESS PREFERRED 5 4.8 100.0 NOT PREFERRED 0 0.0 100.0 Total 105 100.0 Figure 5.16 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-SCIENTIFIC SUPPORT FROM COMPANY) INTERPRETATION: During research it was found that 58.1% doctors highly prefer and 22.9% doctors prefer to consider scientific support from company for selection of brand, 14.3% doctors moderately prefer to consider scientific support from company for selection of brand while 4.8% doctors less prefer to consider scientific support for selection of company. 61 24 15 5 0 0 10 20 30 40 50 60 70 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION SCIENTIFIC SUPPORT FROM COMPANY NO. OF DOCTORS
  54. 54.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page38 5.10.11 All criteria for selection of company Table 5.14 RECOMMANDED DATA (OVERALL PREFERENCE FOR SELECTION OF COMPANY) Criteria Highly Preferred Preferred Moderately Preferred Less Preferred Not Preferred Avg. score Regular visit of MR 95 8 2 0 0 4.88 Samples 82 13 5 5 0 4.63 Knowledge update program by the company 76 12 11 6 0 4.50 Scientific literature provided by company 80 20 3 2 0 4.69 Scientific support provided by company 61 24 15 5 0 4.34 Figure 5.17 RECOMMANDED DATA ANALYSIS (OVERALL PREFERENCE FOR SELECTION OF COMPANY) INTERPRETATION: During research it was found that doctors consider regular MR visit (97.6%) for selection of company. That is followed by scientific literature 4.88 4.63 4.5 4.69 4.34 4 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5 Regular visit of MR Samples Knowledge update program by the company Scientific literature provided by company Scientific support provided by company OVERALL PREFERENCE FOR SELECTION OF COMPANY AVG. SCORE
  55. 55.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page39 provided by company (93.8%), samples (92.6%), knowledge update program (90%) and scientific support from company (86.8%).
  56. 56.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page40 5.11 Considering Factors for Brand Selection: 5.11.1 Price: Table 5.15 RECOMMANDED DATA (BRAND SELECTION-PRICE) PRICE Frequency Percent Cumulative Percent HIGHLY PREFERRED 25 23.8 23.8 PREFERRED 18 17.1 41.0 MODERATELY PREFERRED 1 0.9 41.9 LESS PREFERRED 21 20.0 61.9 NOT PREFERRED 40 38.1 100.0 Total 105 100.0 Figure 5.18 RECOMMANDED DATA ANALYSIS (BRAND SELECTION-PRICE) INTERPRETATION: During research it was found that 23.8% doctors highly prefer and 17.1% doctors prefer to consider price as important factor for brand selection.0.9% doctors moderately prefer to consider price for brand selection. While 20% doctors less prefer and 38.1% doctors don’t prefer to consider price as an important factor during brand selection. 25 18 1 21 40 0 5 10 15 20 25 30 35 40 45 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION BRAND SELECTION-PRICE NO. OF DOCTORS
  57. 57.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page41 5.11.2 Company image: Table 5.16 RECOMMANDED DATA (BRAND SELECTION-COMPANY IMAGE) COMPANY IMAGE Frequency Percent Cumulative Percent N HIGHLY PREFERRED 75 71.4 71.4 PREFERRED 10 9.5 81.0 MODERATELY PREFERRED 12 11.4 92.4 LESS PREFERRED 8 7.6 100.0 NOT PREFERRED 0 0.0 100.0 Total 105 100.0 Figure 5.19 RECOMMANDED DATA ANALYSIS (BRAND SELECTION-COMPANY IMAGE) INTERPRETATION: During research it was found that 71.4% doctors highly prefer and 9.5% doctors prefer to consider company image in brand selection. 11.4% doctors moderately prefer to consider company image in brand selection. While 7.6% doctors less prefer to consider company image in brand selection. 75 10 12 8 0 0 10 20 30 40 50 60 70 80 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION BRAND SELECTION-COMPANY IMAGE NO. OF DOCTORS
  58. 58.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page42 5.11.3 Availability: Table 5.17 RECOMMANDED DATA (BRAND SELECTION-AVAILABILITY) AVAILABILITY Frequency Percent Cumulative Percent HIGHLY PREFERRED 0 0.0 0.0 PREFERRED 1 0.9 0.9 MODERATELY PREFERRED 3 2.9 3.8 LESS PREFERRED 11 10.5 14.3 NOT PREFERRED 90 85.7 100.0 Total 105 100.0 Figure 5.20 RECOMMANDED DATA ANALYSIS (BRAND SELECTION-AVAILABILITY) INTERPRETATION: During research it was found that 0.9% doctors prefer to consider availability in brand selection. 2.9% doctors moderately prefer to consider availability in brand selection. 14.3% doctors less prefer while 85.7% doctors not prefer to consider availability in brand selection. 0 1 3 11 90 0 10 20 30 40 50 60 70 80 90 100 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION BRAND SELECTION-AVAILABILITY NO. OF DOCTORS
  59. 59.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page43 5.11.4 Effectiveness: Table 5.18 RECOMMANDED DATA (BRAND SELECTION-EFFECTIVENESS) EFFECTIVENESS Frequency Percent Cumulative Percent HIGHLY PREFERRED 10 9.5 9.5 PREFERRED 19 18.1 27.6 MODERATELY PREFERRED 5 4.8 32.4 LESS PREFERRED 71 67.6 100.0 NOT PREFERRED 0 0.0 100.0 Total 105 100.0 Figure 5.21 RECOMMANDED DATA ANALYSIS (BRAND SELECTION-EFFECTIVENESS) INTERPRETATION: During research it was found that 9.5% doctors highly prefer and 18.1% doctors prefer to consider effectiveness in brand selection. 4.8% doctors moderately prefer to consider effectiveness in brand selection. While 67.6% doctors less prefer to consider effectiveness in brand selection. 10 19 5 71 0 0 10 20 30 40 50 60 70 80 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION BRAND SELECTION-EFFECTIVENESS NO. OF DOCTORS
  60. 60.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page44 5.11.5 Unique tablet formulation: Table 5.19 RECOMMANDED DATA (BRAND SELECTION-UNIQUE TABLET FORMULATION) UNIQUE TABLET FORMULATION Frequency Percent Cumulative Percent HIGHLY PREFERRED 0 0.0 0.0 PREFERRED 0 0.0 0.0 MODERATELY PREFERRED 1 0.9 0.9 LESS PREFERRED 2 1.9 2.9 NOT PREFERRED 102 97.1 100.0 Total 105 100.0 Figure 5.22 RECOMMANDED DATA (BRAND SELECTION-UNIQUE TABLET FORMULATION) INTERPRETATION: During research it was found that 0.9% doctors moderately prefer to consider unique tablet formulation in brand selection. 1.9% doctors less prefers while 97.1% doctors don’t prefer to consider unique tablet formulation in brand selection. 0 0 1 2 102 0 20 40 60 80 100 120 HIGHLY PREFERRED PREFERRED MODERATELY PREFERRED LESS PREFERRED NOT PREFERRED NO.OFDOCTORS PREFERENCE OF SELECTION BRAND SELECTION-UNIQUE TABLET FORMULATION NO. OF DOCTORS
  61. 61.  DATA ANALYSIS  CHAPTER 5 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page45 5.11.6 Overall preference for selection of Glimepiride+Metformin brand: Table 5.20 RECOMMANDED DATA (OVERALL PREFERENCE FOR BRAND SELECTION) Factors Highly Preferred Preferred Moderately Preferred Less Preferred Not Preferred Avg. Score Price 25 18 1 21 40 2.68 Company image 75 10 12 8 0 4.44 Availability 0 1 3 11 90 1.19 Effectiveness 10 19 5 71 0 2.69 Unique tablet formulation 0 0 1 2 102 1.03 Figure 5.23 RECOMMANDED DATA (OVERALL PREFERENCE FOR BRAND SELECTION) INTERPRETATION: During research it was found that doctors highly prefer to consider company image (88.8%) for brand selection. That is followed by effectiveness (53.8%), price (53.6%), availability (23.8%) and scientific unique tablet formulation (20.6%). 2.68 4.44 1.19 2.69 1.03 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Price Company image Availability Effectiveness Unique tablet formulation AVG.SCORE FACTORS FOR BRAND SELECTION OVERALL PREFERENCE FOR BRAND SELECTION AVG. SCORE
  62. 62. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page46 CHAPTER 6: FINDINGS  About 16% doctors use Glimepiride+Metformin for type-2 diabetes mellitus.  For selection of Glimepiride+Metformin brand doctors mostly prefer company image, effectiveness and price of the product.  Most of doctors about 23% each prescribe Zoryl (Intas) and Glycomet GP (USV) brands and mostly doctors prescribe this brand because of good efficiency.  Mostly use Glimepiride+Metformin strength in market is Glimepiride- 1mg+Metformin-500mg.  Glimepiride+Metformin future demand is high as per the doctors’ opinion.  About 45% doctors find adverse reactions like hypoglycemia and stomach pain with Glimepiride+Metformin.
  63. 63. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page47 CHAPTER 7: CONCLUSION I made survey of 105 doctors from North region of Gujarat and study some literature and find that diabetic patient is increase day by day it is indicate demand for anti-diabetic drugs is increase day by day. After market survey I can conclude that demand of Glimepiride+Metformin is high and mostly doctors prescribe Glimepiride-1mg+Metformin-500mg in type-2 diabetic mellitus. So, company should produce this strength of Glimepiride+Metformin for sustain in market and improve selling of product. Regular visit of MR to doctors as well as scientific literature, samples and effectiveness of product should be maintained because doctors are select company and product on the basis of these criteria.
  64. 64. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page48 CHAPTER 8: SUGGESTIONS  Product should be easily available in market and product should have good effectiveness, it is important for new lunched product.  Good efficiency of product should be maintained is important for attracting the doctors to prescribe product.  For promotional strategy providing adequate literature and covering all Doctors and introduce product to them was most important for improving sell of product.  Company should produce Glimepiride-1mg+Metformin-500mg strength because this strength is mostly prescribe by the doctors.
  65. 65. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page49 CHAPTER 9: REFERENCE 1. Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contribution of B-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29 1130-1139, 2006. 2. American Diabetes Association: Standards of medical care in diabetes--2008. Diabetes Care 31 S12-S54, 2008. 3. Cefalu WT, Waldman S, Ryder S: Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: Rationale and specific agents. Clinical Pharmacology and Therapeutics 81 636-649, 2007. 4. Dailey GE: Glyburide/metformin tablets: A new therapeutic option for the management of type 2 diabetes. Expert Opinion on Pharmacotherapy 4 1417-1430, 2003. 5. González-Ortiz M, Martínez-Abundis E: Eficacia y seguridad de la terapia hipoglucemiante oral combinada de glimepirida más metformina en una sola forma farmacéutica en pacientes con diabetes mellitus tipo 2 y falla secundaria a monoterapia con glibenclamida . Revista de Investigacion Clinica 56 327-333, 2004. 6. González-Ortiz, Manuel; Guerrero-Romero, Jesús F.; Violante-Ortiz, Rafael; Wacher- Rodarte, NielsView Profile; Martínez-Abundis, Esperanza; et al.: Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus: Journal of Diabetes and its Complications 376-9 ,Nov 2009 7. http://archive.indianexpress.com/news/indias-diabetes-drugs-market-grew-22--at-- 700-mn/963511 8. http://care.diabetesjournals.org/content/31/Supplement_1/S55.full 9. http://hosted.comm100.com/knowledgebase/Top-10-therapeutic-segments-in-India- by-market-value-and-growth_A72.aspx 10. http://www.business-standard.com/article/companies/pharma-giants-ready-to- harness-diabetes-market-113090300181_1.html 11. http://www.marketresearch.com/Netscribes-India-Pvt-Ltd-v3676/Anti-Diabetic- Pharmaceuticals-India-6881080 12. http://www.ucsfhealth.org/conditions/diabetes_mellitus/treatment.html
  66. 66.  REFERENCE  CHAPTER 9 AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page50 13. K.D Tripathi, Essential of Medical Pharmacology. 6th edition. 2009: Jaypee brothers medical publishers ltd. 14. Kabadi, Mary U.; Kabadi, Udaya M. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus: Clinical Therapeutics: 63-9, Jan 2014 15. Naresh K. Malhotra, D.F.B., Marketing Research. 3rd ed. 2007: Pearson Education Inc. 16. Rendell M: The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64 1339-1358, 2004. 17. Sona Valsaraj, K T Augusti, Varghese Chemmanam* and Regi Jose: EFFECTS OF INSULIN, GLIMEPIRIDE AND COMBINATION THERAPY OF INSULIN AND METFORMIN ON BLOOD SUGAR AND LIPID PROFILE OF NIDDM PATIENTS: Indian Journal of Clinical Biochemistry, 2009 / 24 (2) 175-178 18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183–1197, 1997 19. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167, 2003
  67. 67. AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page51 APPENDIX-I QUESTIONNAIRE Dear respondent, I am Amitsinh Vihol the student of KADI SARVA VISHWAVIDYALAYA MBA PHARMA, GANDHINAGAR. As a part of management studies requirement in MBA (PHARMA), I have to submit a project report based on marketing research. In this context I am doing research on MARKET SURVEY OF DOCTOR PREFERENCE ON GLIMEPIRIDE+METFORMIN AS A PART OF PRELAUNCH ACTIVITY AT MEDPAAR PHARMACEUTICALS. I request you to fill up this questionnaire and help me in my studies. I assure you that this information will be used for academic purpose only. 1. How many patients do you consult during the day? a. 1 to 20 b. 21 to 40 c. 41 to 60 d. 61 to 80 e. More than 80 2. How many patients do you consult related to type-2 diabetes mellitus during the day? a. 1 to 5 b. 6 to 10 c. 11 to 15 d. 16 to 20 e. More than 20 3. Which drug do you mostly prescribe for type-2 diabetic mellitus? a. Glibenclamide b. Glimepiride c. Metformin d. Glimepiride+Metformin e. Pioglitazone f. Rosiglitazone g. Sitagliptin h. Other______________________
  68. 68. APPENDIX-I AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page52 4. Why do you prescribe Glimepiride+Metformin instead of other anti-diabetic drugs? a. Maximum therapeutic effect b. Rapid action c. Minimize side effect d. All a, b and c 5. Which brand do you more prefer for Glimepiride+Metformin? a. Glimestar-M b. Glimy-M c. Glista d. Gemer e. Gloconorm-G f. Other______________________ 6. Which strength do you mostly prescribe the Glimepiride+Metformin? a. Glimepiride-1mg , Metformin-500mg b. Glimepiride-2mg , Metformin-500mg c. Glimepiride-1mg , Metformin-1000mg d. Glimepiride-4mg , Metformin-1000mg e. Glimepiride-1mg , Metformin-850mg f. Other_______________________ 7. Do you find any adverse reaction with Glimepiride+Metformin? a. Yes b. No 8. Your opinion on future demand of Glimepiride+Metformin. Very High Demand High Demand Average Demand Low Demand Very Low Demand 1 2 3 4 5
  69. 69. APPENDIX-I AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page53 9. What is your preference to selection of company? Criteria Highly Preferred Preferred Moderately Preferred Less Preferred Not Preferred Regular visit of MR Samples Knowledge update program by the company Scientific literature provided by company Scientific support provided by company 10. Which factor do you consider for selection of Glimepiride+Metformin brand? Criteria Highly Preferred Preferred Moderately Preferred Less Preferred Not Preferred Price Company image Availability Effectiveness Unique tablet formulation
  70. 70. APPENDIX-I AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014 Page54 Demographic Factors 1) Name:- 2) Age:- – 40 years - 60 years years 3) Sex:- 4) Specification: ………………… 5) Place: …………………..

×